1-11 of 11
Jennifer H. Cooperrider
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Benjamin A Derman, Tadeusz Kubicki, Jennifer H Cooperrider, Anna Pula, Ken Jiang, Mariel Coradin, Ravleen Virdi, Fionn McLoughlin, Luciano Di Stefano, Vincent Bonifay, Caroline Rougé Dubroc, Andrzej J Jakubowiak
Journal: Blood
Blood (2024) 144 (Supplement 1): 1949.
https://doi.org/10.1182/blood-2024-203566
Published: 2024
Journal Articles

Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Tadeusz Kubicki, Kaina Millan, Anna Pula, Henry Raeder, Quinn Hauck, Manoj Bhagwat, Jude Barton, Eyitayo Awe, Soma Das, Daniela Del Gaudio, Sulin Wu, Frank Wen, Jennifer H Cooperrider, Benjamin A Derman, Andrzej J Jakubowiak, Michael W Drazer
Journal: Blood
Blood (2024) 144 (Supplement 1): 3335.
https://doi.org/10.1182/blood-2024-207445
Published: 2024
Journal Articles

Association between Brain-to-Vein Time and Disease Characteristics and Outcomes for Commercial CAR T-Cell Therapy in Multiple Myeloma

Tyra K Grischke, Benjamin A Derman, Andrzej J Jakubowiak, Jennifer H Cooperrider
Journal: Blood
Blood (2024) 144 (Supplement 1): 7857.
https://doi.org/10.1182/blood-2024-210949
Published: 2024
Journal Articles

Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Jennifer H Cooperrider, Diren Arda Arda Karaoglu, Tadeusz Kubicki, Ken Jiang, Ella Postich, Kathryn Kimi Shimamoto, Olivia Arnold, Aubrianna Ramsland, Anna Pula, Jommel Macaraeg, Andrzej J Jakubowiak, Benjamin A Derman, Caner Saygin
Journal: Blood
Blood (2024) 144 (Supplement 1): 253.
https://doi.org/10.1182/blood-2024-208256
Published: 2024
Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Clinical Trials & Observations
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H. Cooperrider, Andrzej J. Jakubowiak, Benjamin A. Derman
Journal: Blood
Blood (2024) 144 (9): 955–963.
https://doi.org/10.1182/blood.2024024041
Published: 2024
Includes: Supplemental data
Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 1982.
https://doi.org/10.1182/blood-2023-182410
Published: 2023
Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Oscar Boutros Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew T Stefka, Ken Jiang, Jennifer H Cooperrider, Ben A Derman, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4715.
https://doi.org/10.1182/blood-2023-189850
Published: 2023
Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, DJ Sakrikar, Gabriella Lakos, Anna Przybylowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wrobel, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H Cooperrider, Andrzej J Jakubowiak, Benjamin A Derman
Journal: Blood
Blood (2023) 142 (Supplement 1): 340.
https://doi.org/10.1182/blood-2023-190209
Published: 2023
Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4747.
https://doi.org/10.1182/blood-2023-185309
Published: 2023
Journal Articles

Global Health Status Inadequately Captures Longitudinal Changes in Quality of Life in Patients Receiving Carfilzomib for Multiple Myeloma: Electronic Patient-Reported Outcomes (ePROs) from a Prospective Observational Study

Ajay Major, Nicole Prabhu, Claire Cunningham, Jennifer H. Cooperrider, Hannah Johnston, Evangelia Andreatos, Martha Gorski, Sarah Major, Brittany D. Wolfe, Eric Kruse, Ben A. Derman, Roberto M. Lang, Andrzej Jakubowiak, Jeanne DeCara
Journal: Blood
Blood (2022) 140 (Supplement 1): 12593–12595.
https://doi.org/10.1182/blood-2022-157795
Published: 2022
Journal Articles

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman, Ajay Major, Sarah Major, Brittany D. Wolfe, Martha Gorski, Jennifer H. Cooperrider, Evangelia Andreatos, Ken Jiang, Karson Buckley, Amanda McIver, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2108–2109.
https://doi.org/10.1182/blood-2022-158643
Published: 2022